ironwoodpharma.com - Wutah bathi EPS kuartalan IRWD

Ironwood Pharmaceuticals, Inc. - logo grafis emiten IRWD

The quarterly EPS growth profile for Ironwood Pharmaceuticals (IRWD) on the GURU.Markets interface demonstrates the impact of the strong pricing power of its patented drug, while 55.60 reflects the latest metric level. The business model relies on outsourcing production and clinical trials to external vendors. Simultaneously, Ironwood Pharmaceuticals (IRWD) faces pressure from generics and new biologics within the competitive gastroenterology landscape.

Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan Ironwood Pharmaceuticals, Inc. (IRWD): kanggo periode 04.07.2022 - 18.11.2026

Rincian metrik komprehensif lan analitis Ironwood Pharma (IRWD)

- rega saham lan konsensus proyeksi valuasi:
Analisis dhasar perusahaan:Ironwood Pharmaceuticals
Produk asil prodhuksi Ironwood Pharmaceuticals, Inc.

This indicator reflects the dynamics of net earnings per share on a quarterly basis. The metric captures the rate of change in profitability, allowing the quarterly variation in EPS to identify whether the asset is overheated or in a growth phase. Trend analysis eliminates market illusions by objectifying the financial result. For Ironwood Pharmaceuticals (IRWD), the stability of this metric is supported by the optimization of production costs. Outsourcing drug manufacturing to third-party behemoths minimizes operational downtime.